Belpointe Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,598
| Closed | -$1.54M | – | 1197 |
|
|
2025
Q4 | $1.54M | Buy |
12,598
+5,605
| +80% | +$643K | 0.06% | 289 |
|
|
2025
Q3 | $701K | Buy |
+6,993
| New | +$630K | 0.03% | 519 |
|
|
2025
Q1 | – | Sell |
-10,393
| Closed | -$1.05M | – | 1045 |
|
|
2024
Q4 | $1.05M | Buy |
10,393
+92
| +0.9% | +$8.91K | 0.06% | 301 |
|
|
2024
Q3 | $1.02M | Sell |
10,301
-1,081
| -9% | -$106K | 0.06% | 311 |
|
|
2024
Q2 | $1.06M | Buy |
11,382
+2,672
| +31% | +$240K | 0.07% | 257 |
|
|
2024
Q1 | $826K | Sell |
8,710
-5,214
| -37% | -$484K | 0.06% | 318 |
|
|
2023
Q4 | $1.24M | Buy |
13,924
+9,586
| +221% | +$712K | 0.11% | 184 |
|
|
2023
Q3 | $317K | Sell |
4,338
-6,099
| -58% | -$487K | 0.03% | 455 |
|
|
2023
Q2 | $868K | Buy |
10,437
+883
| +9% | +$73.8K | 0.09% | 211 |
|
|
2023
Q1 | $728K | Sell |
9,554
-882
| -8% | -$73.2K | 0.04% | 420 |
|
|
2022
Q4 | $866K | Sell |
10,436
-2,335
| -18% | -$189K | 0.05% | 361 |
|
|
2022
Q3 | $1.01M | Buy |
12,771
+1,553
| +14% | +$131K | 0.07% | 289 |
|
|
2022
Q2 | $834K | Buy |
11,218
+6,240
| +125% | +$468K | 0.06% | 343 |
|
|
2022
Q1 | $448K | Sell |
4,978
-511
| -9% | -$47.2K | 0.03% | 573 |
|
|
2021
Q4 | $614K | Sell |
5,489
-120
| -2% | -$14.5K | 0.04% | 459 |
|
|
2021
Q3 | $705K | Buy |
5,609
+1,297
| +30% | +$167K | 0.05% | 407 |
|
|
2021
Q2 | $584K | Sell |
4,312
-14,207
| -77% | -$1.87M | 0.04% | 449 |
|
|
2021
Q1 | $2.51M | Sell |
18,519
-1,191
| -6% | -$178K | 0.22% | 94 |
|
|
2020
Q4 | $2.77M | Sell |
19,710
-5,238
| -21% | -$671K | 0.25% | 84 |
|
|
2020
Q3 | $2.78M | Sell |
24,948
-5,466
| -18% | -$613K | 0.31% | 66 |
|
|
2020
Q2 | $3.4M | Buy |
30,414
+13,189
| +77% | +$1.3M | 0.44% | 43 |
|
|
2020
Q1 | $1.33M | Sell |
17,225
-10,412
| -38% | -$922K | 0.23% | 101 |
|
|
2019
Q4 | $2.63M | Buy |
27,637
+23,248
| +530% | +$2.01M | 0.33% | 75 |
|
|
2019
Q3 | $335K | Sell |
4,389
-17,754
| -80% | -$1.48M | 0.05% | 371 |
|
|
2019
Q2 | $1.94M | Buy |
+22,143
| New | +$1.89M | 0.38% | 52 |
|
|
2019
Q1 | – | Sell |
-4,125
| Closed | -$296K | – | 593 |
|
|
2018
Q4 | $296K | Sell |
4,125
-33,025
| -89% | -$2.66M | 0.08% | 281 |
|
|
2018
Q3 | $3.56M | Sell |
37,150
-698
| -2% | -$67.7K | 0.56% | 26 |
|
|
2018
Q2 | $3.6M | Buy |
+37,848
| New | +$3.48M | 1.01% | 11 |
|
|
2018
Q1 | – | Sell |
-2,756
| Closed | -$234K | – | 494 |
|
|
2017
Q4 | $234K | Buy |
+2,756
| New | +$231K | 0.05% | 390 |
|
Other funds holding XBI
Belpointe Asset Management's XBI Position: Q1 2026 in Review
Belpointe Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 12,598 shares — an estimated $1.54M sold.
Belpointe Asset Management first reported a position in XBI in Q4 2017 and held it in 29 quarters. The position peaked at $3.6M in Q2 2018. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Belpointe Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
- Belpointe Asset Management sold 12,598 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.54M.
- Belpointe Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 29 quarters.
- Belpointe Asset Management's State Street SPDR S&P Biotech ETF position peaked at $3.6M in Q2 2018.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.